恒瑞医药子公司RSS0393软膏临床试验获批

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Ruishi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of RSS0393 ointment, which will commence shortly [1] Group 1: Product Development - RSS0393 ointment is a self-developed product by Heng Rui Medicine, containing a PDE4 small molecule inhibitor [1] - The ointment is designed to alleviate tissue damage and inflammation by inhibiting PDE4 activity in various cells upon application [1]